This study was done to find out the prevalence of fatty liver in type2 Diabetic patients. This was a descriptive cross-sectional comparative study carried out in Department of Medicine, Rajshahi Medical College Hospital and Rajshahi Diabetic Association Hospital from July 2008 to June 2010. 100 (one hundred) diagnosed type2 diabetic patients were included. All of those study population were free from taking any hepatoxic drugs and free from any preexisting liver disease. This exclusion was done by history, through clinical examination and relevant investigations. Among 100 type2 diabetic patients, 66 (66%) had normal, 25 (25%) had mild fatty change, 6 (6%) had moderate fatty change in liver; 2 (2%) had mild hepatomegally and 1 (1%) had congested liver. Non had cirrhosis or hepatocellular carcinoma.
Introduction
Diabetes mellitus is a common metabolic disorder characterized by hyperglycaemia due to absolute or relative deficiency of insulin. The world wide prevalence of DM has risen dramatically over the past two decades, from an estimated 30 million case in 1985 to 177 million in 2000. Based on current trends>360 million individuals will have diabetes by the year2030. 1 Diabetes mellitus is a growing health problem that causes significant morbidity and mortality. 2 Although the prevalence of both type 1 and type2 DM is increasing world wide, the prevalence of type2 DM is rising much, more rapidly. Type 2 DM is principally a disease of the middle-age and elderly, typical age of onset is >40 years. In individuals>60 years, the prevalence of DM was 20.9% and over 70% of all case of diabetes occur after the age of 50 years. 3 Hepatic fat accumulation is a well-recognized complication of diabetes with a reported frequency of 40-70%. Unfortunately, associated obesity is a frequently occurring confounding variable. Type 1 diabetes is not associated with fat accumulation if glycemia is well controlled, but type 2 diabetes may have a 70% correlation regardless of blood glucose control. 
Material and Methods
This was a descriptive cross-sectional comparative study carried out in Department of Medicine, Rajshahi Medical College Hospital and Rajshahi Diabetic Association Hospital from July 2008 to June 2010. 100 (one hundred) diagnosed type2 diabetic patients and 30 apparently healthy people were included. All of those study population were free from taking any hepatoxic drugs and free from any preexisting liver disease. This exclusion was done by history, through clinical examination and relevant investigations.
Results
Among 100 type2 diabetic patients, 66 (66%) had normal , 25 (25%) had mild fatty change, 6 (6%) had moderate fatty change in liver; 2 (2%) had mild hepatomegally and 1 (1%) had congested liver. Non had cirrhosis or hepatocellular carcinoma. 1 Virtually the entire spectrum of liver disease is seen in patients with type-2 diabetes. This includes abnormal live enzymes, non alcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma and acute liver failure. 5 Salmela et al 6 done liver biopsy of 68 patients of type-2 diabetes having abnormal LFTs. Of the 68 patients 5 had normal liver histology and 63 patients with abnormal liver histology, 48 had fatty liver or steatosis with non-specific inflammatory change, whereas 14 had evidence of fibrosis. In our study we did not done any liver biopsy. Cusi and Kenneth 7 in 2009 showed that approximately 70% person with type-2 diabetes mellitus had a fatty liver and the disease follows a more aggressive course with necroinflammation and fibrosis. New evidence suggests that it is not steatosis per se but the development of lipotoxicity-induced mitochondrial dysfunction and activation of inflammatory pathways that leads to progressive liver damage. Non alcoholic steotohepatitis is a leading cause of end-stage liver disease. In our study fatty liver is common which was 31%, among theme 25% had mild fatty change and only 6% had moderate fatty change.
Conclusion
A high proportion of patients with type-2 diabetes mellitus in our country have abnormal liver function tests that may be a marker of NASH and insulin resistance.
